Treasurer of the State of North Carolina Boosts Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Treasurer of the State of North Carolina grew its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNYFree Report) by 0.9% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 86,697 shares of the biopharmaceutical company’s stock after buying an additional 740 shares during the quarter. Treasurer of the State of North Carolina owned 0.07% of Alnylam Pharmaceuticals worth $16,595,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also made changes to their positions in ALNY. Quent Capital LLC increased its position in Alnylam Pharmaceuticals by 246.0% during the fourth quarter. Quent Capital LLC now owns 173 shares of the biopharmaceutical company’s stock worth $33,000 after buying an additional 123 shares in the last quarter. Anchor Investment Management LLC acquired a new stake in shares of Alnylam Pharmaceuticals during the 4th quarter worth about $38,000. Robeco Institutional Asset Management B.V. raised its position in shares of Alnylam Pharmaceuticals by 155.7% in the fourth quarter. Robeco Institutional Asset Management B.V. now owns 20,549 shares of the biopharmaceutical company’s stock valued at $39,000 after buying an additional 12,513 shares during the last quarter. GAMMA Investing LLC purchased a new position in shares of Alnylam Pharmaceuticals during the fourth quarter valued at approximately $52,000. Finally, Lindbrook Capital LLC grew its stake in Alnylam Pharmaceuticals by 37.2% in the 4th quarter. Lindbrook Capital LLC now owns 369 shares of the biopharmaceutical company’s stock worth $71,000 after acquiring an additional 100 shares during the period. Institutional investors and hedge funds own 92.97% of the company’s stock.

Analyst Ratings Changes

Several equities analysts recently commented on the company. JPMorgan Chase & Co. upped their target price on Alnylam Pharmaceuticals from $150.00 to $170.00 and gave the company a “neutral” rating in a research note on Thursday, February 1st. HC Wainwright raised their target price on shares of Alnylam Pharmaceuticals from $395.00 to $400.00 and gave the stock a “buy” rating in a research report on Tuesday, May 7th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $235.00 price target on shares of Alnylam Pharmaceuticals in a research note on Tuesday, February 20th. William Blair reissued an “outperform” rating on shares of Alnylam Pharmaceuticals in a research note on Monday, April 8th. Finally, The Goldman Sachs Group cut Alnylam Pharmaceuticals from a “buy” rating to a “neutral” rating and reduced their target price for the company from $230.00 to $173.00 in a report on Friday, February 16th. Seven analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the stock. Based on data from MarketBeat.com, Alnylam Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus target price of $216.19.

Read Our Latest Report on ALNY

Alnylam Pharmaceuticals Trading Up 2.1 %

Shares of Alnylam Pharmaceuticals stock opened at $150.03 on Friday. Alnylam Pharmaceuticals, Inc. has a twelve month low of $141.98 and a twelve month high of $218.88. The business’s 50 day simple moving average is $149.39 and its 200-day simple moving average is $163.71.

Alnylam Pharmaceuticals (NASDAQ:ALNYGet Free Report) last announced its quarterly earnings results on Thursday, May 2nd. The biopharmaceutical company reported ($0.52) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.75) by $0.23. The firm had revenue of $494.33 million for the quarter, compared to analyst estimates of $428.01 million. The business’s revenue was up 54.8% compared to the same quarter last year. During the same period last year, the firm posted ($1.40) EPS. Research analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -3.77 earnings per share for the current fiscal year.

Alnylam Pharmaceuticals Company Profile

(Free Report)

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.

Recommended Stories

Institutional Ownership by Quarter for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.